Real-time Quotes | Nasdaq Last Sale

After Hours: 2.990 +0.07 +2.40% 16:31 11/25 EST
Corp Actions
ISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Managements WHITE Consent Card
WaterMill Asset Management Corp. (together with its affiliates, "WaterMill" or "we"), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm" or the "Company"), today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy voting advisory firm, recommends shareholders vote for boardroom change on the WHITE consent card. In particular, ISS supports the addition of two WaterMill nominees – Jaime Vieser and Holger Weis – to Ziopharm’s Board of Directors (the "Board"). ISS also recommends for the removal of two incumbents – Chairman Scott Tarriff and Director Elan Ezickson – from the Company’s Board.
Business Wire · 20h ago
ISS backs two of three of activist's board nominees at Ziopharm Oncology
Reuters · 20h ago
WaterMill Asset Management Sets the Record Straight Following Ziopharms Apparent Attempt to Mislead Shareholders and Rewrite History
WaterMill Asset Management Corp. (together with its affiliates, "WaterMill" or "we"), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm" or the "Company"), today released a new rebuttal presentation in response to the incumbent Board of Directors’ (the "Board") recent attempt to mislead shareholders and rewrite history regarding Ziopharm’s relationship with Intrexon Corporation ("Intrexon"), which has been renamed Precigen Incorporated ("Precigen"). We invite shareholders to download and view the full presentation here.
Business Wire · 2d ago
Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution
Ziopharm Oncology ([[ZIOP]] +4.2%) today released an investor presentation highlighting its successful developments, as well as says 75% of its current directors joined after separation from Intrexon, and have relevant
Seekingalpha · 6d ago
Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Shareholder Value
Continues to Execute on Strategy to Ensure Strong Long-Term OutlookOutlines Additions of Five Highly Qualified Industry Veterans to Board Over the Last 18 MonthsBOSTON, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission detailing the Company’s track record of successful developments and accomplishments within the oncology space as well as its commitment to evolving its Board of Directors (the “Board”) to drive shareholder value.Highlights from the Ziopharm investor presentation include: * Ziopharm’s significant progress on its strategy to develop and commercialize non-viral and cytokine-driven cell and gene therapies to treat the millions of people globally diagnosed with a solid tumor each year since its separation from Precigen in 2018; * Significant anticipated pipeline development milestones expected to enhance shareholder value; and * The Board’s governance changes and continued commitment to refreshing and enhancing its membership, with more than half of the current directors being appointed to the Board since June 2019, a process undertaken following shareholder feedback. Commenting on the investor presentation, Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, stated, “Over the course of the past several weeks, we have continued to address shareholder feedback with additional Board changes in the appointment of Mary Thistle and resignation of Dr. Scott Braunstein. We also reported key new executive hires and strong third quarter results that demonstrate our continued execution and clinical progress to advance our mission to treat cancer patients with potentially transformational therapies. Our recent investor presentation outlines these positive changes and strategic initiatives as well as an array of other facts and upcoming catalysts that we believe help advance our goal of delivering long-term shareholder value.”Industry analysts who closely follow Ziopharm have noted this progress and outlook, illustrated by the below selected commentary: * “By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.”1 * “ZIOP is a refreshed, and unencumbered oncology story, with two exciting technology platforms.”2 * “We believe ZIOP is doing everything it proactively can, to hit the ground running with the TCR T trials, with two INDs …this opportunistic move will likely yield long term benefits for the program.”3 Ziopharm recommends shareholders sign and return the Company’s GREEN Consent Revocation Card. The investor presentation and other important materials related to the WaterMill consent solicitation can be found at Ziopharm Oncology, Inc. Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the growth of Ziopharm from a development-stage entity to a commercial-stage company, development of its clinical portfolio and research and development programs. Although Ziopharm’s management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharm’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharm’s intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharm’s Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.Important Additional Information and Where to Find It Ziopharm has filed a definitive consent revocation statement (the “Consent Revocation Statement”) together with a GREEN consent revocation card with the SEC in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Consent Revocation Statement (including the GREEN consent revocation card), any amendments or supplements thereto and any other documents that Ziopharm files with the SEC from the SEC’s website ( or from Ziopharm’s website ( by clicking on “Investors” and then “SEC Filings.”Investor Relations Contacts: Adam D. Levy, PhD, MBA EVP, Investor Relations and Corporate Communications (508) 552-9255 Chris Taylor VP, Investor Relations and Corporate Communications (617) 502-1881 ctaylor@ziopharm.comMichael Verrechia Morrow Sodali (212) 300-2476 Media Relations Contacts: Chris Kittredge, Andrew Cole and Zachary Tramonti Sard Verbinnen & Co. 1 Lake Street Capital, “Wait Continues for Patient Enrollments In T-Cell Programs,” (November 6, 2020) Permission to quote third parties neither requested nor granted. 2 Jefferies Group, “3Q20: Library TCRT IND on Track in 1Q21; IL12 Updates at SNO,” (November 6, 2020) Permission to quote third parties neither requested nor granted. 3 Cantor Fitzgerald, “2Q Update: Solid clinical execution on pipeline, in light of pandemic headwinds,” (August 12, 2020) Permission to quote third parties neither requested nor granted.
GlobeNewswire · 6d ago
WaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm Oncology
WaterMill Asset Management Corp. (together with its affiliates, "WaterMill" or "we"), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm" or the "Company"), today released a 55-page presentation that details the case for urgent change in the boardroom and summarizes its director candidates’ value-enhancing vision. As a reminder, WaterMill is seeking to reconstitute Ziopharm’s eight-member Board of Directors (the "Board") by removing four incumbent directors and electing three highly-qualified and independent individuals: Robert Postma, Jaime Vieser and Holger Weis.
Business Wire · 11/19 14:30
Ziopharm Oncology Highlights Presentation Of Data For Controlled IL-12 At 2020 Society For Neuro-Oncology Annual Meeting
– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM, and a Confirmed Partial Response – – Updated Interim Data
Benzinga · 11/19 14:10
White Rock Capital Supports WaterMill's Case for Change at Ziopharm Oncology
White Rock Capital Partners, L.P. ("White Rock Capital"), along with all of its related entities, will vote 100% of its approximately 6.1 million common shares (which excludes 3.8 million warrants) of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm" or the "Company") in support of WaterMill Asset Management Corp.'s proposal for a reconstituted Board of Directors.
PR Newswire · 11/19 14:00
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZIOP. Analyze the recent business situations of ZIOPHARM Oncolgy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZIOP stock price target is 5.93 with a high estimate of 7.50 and a low estimate of 3.000.
Institutional Holdings
Institutions: 246
Institutional Holdings: 110.76M
% Owned: 51.69%
Shares Outstanding: 214.29M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Chairman/Independent Director
Scott Tarriff
Chief Executive Officer/Director
Laurence Cooper
Chief Financial Officer
Satyavrat Shukla
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Robert Hadfield
Executive Vice President/General Manager
Jill Buck
Vice President/Director of Investor Relations
David Connolly
Executive Vice President/General Manager
Eleanor De Groot
Executive Vice President/Director of Human Resources
Lynn Ferrucci
Senior Vice President - Finance/Chief Accounting Officer/Treasurer
Kevin Lafond
Raffaele Baffa
J. Kevin Buchi
James Huang
Independent Director
Christopher Bowden
Independent Director
Elan Ezickson
Independent Director
Heidi Hagen
Independent Director
Mary Thistle
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Hot Stocks

Webull offers kinds of ZIOPHARM Oncology Inc. stock information, including NASDAQ:ZIOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZIOP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZIOP stock methods without spending real money on the virtual paper trading platform.